source
- Lilly and FDA clash over retatrutide classification as company nears submissionEli Lilly is preparing to file its obesity drug candidate retatrutide for approval while a legal dispute with the FDA over the drug's classification intensifies. The agency has concluded that reta…
- Lilly's Foundayo obesity pill posts $98 million Q2 sales, trails Novo's WegovyEli Lilly introduced its oral obesity treatment Foundayo after receiving FDA approval in April 2025. The drug entered the market in the second quarter of 2026, marking Lilly's first foray into an o…